Currently the global prevalence of non-alcoholic fatty liver disease (NAFLD) is estimated to be around 25% for the general adult population [1], with estimates over 50% in populations with type 2 diabetes mellitus [2]. Meta-analyses by Dulai et al. (2017) and Taylor et al. (2020) indicate that liver fibrosis in NAFLD is an independent risk factor for all-cause mortality and liver-related mortality [3,4]. This underscores the need to stage NAFLD in order to detect patients with advanced stage fibrosis or cirrhosis
